J&J, AstraZeneca explore Covid-19 vaccine modification after blood clot reports
Vials of Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine candidate are seen in an undated photograph. Johnson & Johnson/Handout via REUTERS.
Johnson & Johnson and AstraZeneca are conducting early-stage research into whether potential modifications to their Covid-19 vaccines could reduce or eliminate the risk of rare but serious blood clots linked to the shots, the Wall Street Journal reported, citing people close to the process.
Keep updated, follow The Business Standard's Google news channel
